We examined sera from 113 patientswith myastheniagravis (MG). Most of the patients with ocular MG without thymoma and 15% of the patients with generalized MG had immunoprecipitation (IP) titers of anti-acetylcholine receptor (antiAChR) antibodies within the normal range for healthy subjects. We developed a highly sensitive radioassay using 
MG patients without thymoma. We detected no anti-AChR antibodies in nearly all patients with various immunological and neurologicaldiseases other than MG, and in all the healthy controls. The data for these sera indicate that in some cases the standard IP assay gives false-negative reactions. Thus, use of the more sensitive radioassay is preferable for accuracy.
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The muscular weakness and fatigability seen in myasthenia gravis (MG) result from an antibody-mediated immime response to acetylcholine receptor (AChR).4 Among anti-AChR antibodies, non-blocking-type antibodies measured by the standard immunoprecipitation (IP) assay were detectedin 85-90% of myasthenic patients (1) (2) (3) , and were shown to have a key role in producingthe basic defects in MG. Therefore, detectionofcirculating anti-AChR antibodies is at present the clinical standard for definitive diagnosis of MG. In a previous study (3) , involving sera from a large number of Japanese patients with MG, we confirmed that patients with generalized MG had a high prevalence (85%) of anti-AChR antibodies. centrifuging, as above, we counted the radioactivity in the cell pellet by using a gamma counter. In this assay, values >0.07 nmol/L (the mean for the normal controls plus 3 SD: 0.04 + 0.03 nmol/L) were considered positive.
Results
The standard curve for anti-AChR antibody by this assay showed a linear relationship between amount of labeled a-BuTx capable of binding to the cells and the amount of the anti-AChR antibody in the range of 0.07-5 nmoIJL. Therefore, this assay system may be applicable to serum samples with anti-AChR antibody titers less than the detection limit (<0.6 nmol/L) of the standard IF assay. Figure 1 showsthat this assay also detected all those sera that were positiveby IF assay. The accuracy and specificity of this method were confirmed by the good correlation with results by the IF assay in these positive cases(r = 0.91).
We alsore-examined 86 myasthenic sera for which titers of anti-AChR antibodies were within the normal range (<0.6 nmol/L) by the IF assay (Figure 2) . The radioassay detected anti-AChR antibodies in 19 of 50 subjectswith ocular MG without thymoma, in five of 31 with generalized MG without thymoma, in two of three with ocular MG with thymoma, and in one of two with generalized MG with thymoma. In all, 31% (27 of 86) of the IF-negative myasthenic sera tested had positive titers by radioassay, although these titers were extremely low (0.07-0.6 ninollL). Most of these 27 cases (19) were from ocular MG patients without thymoma. By using the combination of the standard IF assay and our modified radioassay, we increased the overall percent positivity of non-blocking-type antibodies in ocular MG with thymoma to 48%.
We also used the radioassay to screen various immunological and neurological diseases other than MG. Nearly all of these sera and all healthy control sera showed no titers of anti-AChR antibodies, although low antibody titers were found in two cases with thymoma but not MG (Figure 2 ).
DiscussIon
Non-blocking-type
anti-AChR antibodies detected by the IF assay have been thought to be the major antibodies in MG sera because of their high frequency of detection. reported that ocular patients have low anti-AChR, but also that these antibodies react equally well with AChR extracted from ocular or limb-muscle tissue, whereas sera from patients with generalized disease react better with AChR from limb muscle. When we measured anti-AChR antibodiesby using bovineextraocular musclesas antigen, we could not find detectable antibodies in ocular MG patients (data not shown). We detected extremely low titers of anti-AChR antibodies in two of the seven patients with thymoma but no MG. Similar observations have been reported for the standard IF assay (8-10). We have observed some patients who developed MG during treatment with D-penicillanhine for rheumatoid arthritis. These patients had increased titers of anti-AChR antibodies, whereas after withdrawal of the drug, the titer of the antibodies decreased rapidly and any clinical sign of neuromuscular disorder rapidly disappeared. Using the radioassay, we examined the AChR antibodies in 10 patients with rheumatoid arthritis while they were receiving D-penicillamine treatment; these pa-tients had neither anti-AChR antibodies by IP assay nor any clinical sign of MG. No detectable anti-AChR antibodies were found in these patients. Kyriatsoulis A) from ATP in the presenceof double-strandedRNA, and 2-5 A activates endonuclease (1) (2) (3) . Because IFN may inhibit viral replication in this way, endonucleasemay play an important role in the antiviral action of IFN. Increased concentrations of ribonuclease (RNase; EC 3.1.27.5) activity in human serum have been reported in cases of renal failure (4, 5) , pancreatic cancer (6) , multiple myeloma (7) , leukemia (8), and other diseases (9). However, the effect of IFN therapy on RNase activity in serum has not been previously reported.
Effects of Recombinant Leukocyte Interferon on Ribonuclease Activities in Serum in Chronic
Recently, recombinant human leukocyte IFN has been used for treating chronic hepatitis B virus (HBV) infection.
